KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Gross Margin (2017 - 2025)

Amneal Pharmaceuticals has reported Gross Margin over the past 9 years, most recently at 36.5% for Q4 2025.

  • Quarterly results put Gross Margin at 36.5% for Q4 2025, up 51.0% from a year ago — trailing twelve months through Dec 2025 was 36.88% (up 36.0% YoY), and the annual figure for FY2025 was 36.88%, up 36.0%.
  • Gross Margin for Q4 2025 was 36.5% at Amneal Pharmaceuticals, up from 34.92% in the prior quarter.
  • Over the last five years, Gross Margin for AMRX hit a ceiling of 39.71% in Q2 2021 and a floor of 30.77% in Q4 2023.
  • Median Gross Margin over the past 5 years was 36.05% (2024), compared with a mean of 35.99%.
  • Biggest five-year swings in Gross Margin: skyrocketed 4526bps in 2021 and later crashed -456bps in 2023.
  • Amneal Pharmaceuticals' Gross Margin stood at 30.99% in 2021, then grew by 14bps to 35.32% in 2022, then dropped by -13bps to 30.77% in 2023, then increased by 17bps to 35.98% in 2024, then grew by 1bps to 36.5% in 2025.
  • The last three reported values for Gross Margin were 36.5% (Q4 2025), 34.92% (Q3 2025), and 39.51% (Q2 2025) per Business Quant data.